logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Pulmonary Embolism

    FiltersReset Filters
    26 results

    • activase

      (Alteplase)
      Genentech, Inc.
      Usage: Activase is indicated for the treatment of acute ischemic stroke, acute myocardial infarction (AMI) to reduce mortality and heart failure incidence, and lysis of acute massive pulmonary embolism with significant obstruction or unstable hemodynamics. Treatment should be initiated quickly, particularly for stroke within 3 hours of symptom onset.

    • apixaban

      (Apixaban)
      Macleods Pharmaceuticals Limited
      Usage: Apixaban is indicated for reducing stroke and systemic embolism risk in nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis following hip or knee surgery, and treatment of deep vein thrombosis and pulmonary embolism. It also reduces the risk of recurrent DVT and pulmonary embolism after initial therapy.

    • dabigatran etexilate

      (dabigatran etexilate)
      Apotex Corp.
      Usage: Dabigatran etexilate capsules are indicated for reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism, preventing their recurrence, and prophylaxis following hip replacement surgery in adult patients.

    • dabigatran etexilate

      (Dabigatran Etexilate)
      Mylan Pharmaceuticals Inc.
      Usage: Dabigatran etexilate capsules are indicated for reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treating and preventing deep vein thrombosis and pulmonary embolism in adults and pediatric patients aged 8-17, and preventing recurrence of venous thromboembolic events.

    • dabigatran etexilate

      (Dabigatran etexilate)
      Dr. Reddy's Laboratories Inc.
      Usage: Dabigatran etexilate capsules are indicated for reducing stroke risk in non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism, providing prophylaxis following hip replacement surgery, and treating and preventing venous thromboembolic events in pediatric patients aged 8 to under 18 years.

    • dabigatran etexilate

      (Dabigatran Etexilate)
      Alembic Pharmaceuticals Limited
      Usage: Dabigatran etexilate is indicated for reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism, preventing recurrence of these conditions, and prophylaxis following hip replacement surgery in adults.

    • eliquis

      (apixaban)
      E.R. Squibb & Sons, L.L.C.
      Usage: ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, as well as for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It also reduces the risk of recurrence of DVT and PE post-therapy.

    • enoxaparin sodium

      (Enoxaparin Sodium)
      Fresenius Kabi USA, LLC
      Usage: Enoxaparin sodium injection is indicated for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the prevention of ischemic complications in unstable angina and non-Q-wave myocardial infarction. Additionally, it aids in treating acute ST-segment elevation myocardial infarction.

    • fondaparinux sodium

      (Fondaparinux Sodium)
      Sandoz Inc.
      Usage: Fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip or knee surgery and at-risk abdominal surgery. It is also used for treating acute DVT and acute pulmonary embolism in combination with warfarin sodium.

    • fragmin

      (Dalteparin Sodium)
      Pfizer Laboratories Div Pfizer Inc
      Usage: FRAGMIN is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, deep vein thrombosis (DVT) prevention in surgical and at-risk patients, extended treatment of symptomatic VTE in cancer patients, and VTE treatment in pediatric patients. It is not for acute VTE treatment.